



Dated: April 04, 2026

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Sub: Press Release

Dear Sir/Mam,

We are herewith enclosing the press release given by the Company.

This is for your information and dissemination to the members of the exchange.

Thanking You.

For GRANULES INDIA LIMITED

CHAITANYA

TUMMALA

**CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)**

Digitally signed by CHAITANYA TUMMALA
DN: c=IN, postalCode=500085, st=TELANGANA, street=H NO 16-3
V-304, PLOT NO 304, MEDICAL MALAKA GIRIVASANTH
NAGAR, 500085, o=RESCHAL MALAKA GIRI, ou=Personnel,
serialNumber=ac6c5085a4c307805711e3f11abba1f72da48346a26aa5fe
898a52ae0775c-3a59,
pseudonym=17c7d496cf264c208814aa3ba683503,
2.5.4.20b1c7b56dcd76566221a7d9bd0992f5434713381063a856d76
26c209b1d4b5c, email=CHAITANYA.TC@GMAIL.COM, cn=CHAITANYA
TUMMALA
Date: 2026.04.04 15:09:41 +05'30'

REGISTERED OFFICE

Granules India Limited

CIN: L24110TG1991PLC012471

15th Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad – 500084, Telangana, India

Contact Us: Tel: +91-40-69043500 | Fax: +91-40-23115145 | mail@granulesindia.com



Press Release

Granules India Limited completes cGMP Audit at its Chantilly Site

Hyderabad, India – April 4, 2026 – Granules India Limited today announced that its wholly-owned subsidiary, Granules Pharmaceuticals, Inc. (GPI), located in Chantilly, Virginia, US, has completed a routine current Good Manufacturing Practices (cGMP) audit by the US Food and Drug Administration (FDA) with four Form 483 observations.

This inspection was conducted from March 30 to April 3, 2026 and marks the second US FDA inspection at the Chantilly facility in last one year.

The observations are related to procedural matters and no data integrity–related observations were reported during the inspection.

Granules remains committed to maintaining the highest standards of quality, safety, and regulatory compliance and will address the observations raised by the US FDA within the stipulated timelines.

*****END*****



About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs) and Peptides CDMO. Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US and Switzerland. The Company has 10 manufacturing facilities out of which 7 are in India, 2 in the USA and 1 in Switzerland and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.

For more information about Granules India Ltd and its initiatives, please visit www.granulesindia.com.

Safe Harbor: This document is to provide general background information about the Company's activities as at the date of the release. The information contained herein is for general information purposes only and is based on estimates and should not be considered as a recommendation that any investor should subscribe/purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein. This release may include certain "forward- looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, the ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company nor its directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein. No part of this release may be reproduced, quoted or circulated without prior written approval from Granules India Limited.

Media Contact:	Investors Contact:
Priyanka Chawla Corporate Communications priyanka.chawla@granulesindia.com	Chaitanya Tummala Company Secretary 040-69043614 chaitanya.tummala@granulesindia.com